Pratik Jaluria

Excited to announce the 2025 Gordon Research Conference (GRC) on Protein Engineering, this second GRC on Protein Engineering will be held at Bryant University in Smithfield, RI from July 27th to August 1st 2025 https://lnkd.in/g-763SeF. please come join us if you would be interested in this exciting field. Different fields have experienced a transformative expansion in research distinction and capabilities. There now exists a strategic opportunity for protein engineering to take the lead and spearhead the integration of this joint effort, reflected by The Nobel Prize in Chemistry 2024. We believe that this GRC conference will create a gateway for the next generation of engineers and researchers, and will be a vehicle toward future development in the midst of an amazing convergence of multiple cutting-edge areas in protein engineering and its applications. Confirmed speakers include the Nobel Laureate Prof. Frances Arnold and distinctive scientists showing below: 1.            Fundamental Principles of Protein Engineering Possu Huang (Stanford University)/Frances Arnold (CalTech, Nobel Laureate)/Huimin Zhao (University of Illinois at Urbana-Champaign) 2.    Biosensors and Imaging Jennifer Prescher (UC Irvine)/Jin zhang (UC San Diego)/Robert Campbell (Tokyo University)/Nathan Shaner (UC San Diego) 3.    Rational Design of New-to Nature Proteins Jiri Damborsky (FNUSA-ICRC & Masaryk University, Czech Republic)/Joelle Pelletier (University of Montreal)/Sílvia Osuna (University of Girona & ICREA, Spain)/Koga Nobuyasu (Osaka Univ, Japan) 4.    AI for Protein engineering Zhongyue John Yang (Vanderbilt University)/ Jennifer Listgarten (UC Berkeley)/Doug Barrick (Johns Hopkins University) 5.    Biocatalysis and Industrial applications Carlos Martinez (Pfzer)/ Stephanie Galanie (Merck)/Zhi Li (National University of Singapore, Singapore)/Brent Dorr (Ginkgo Bioworks) 6.    Protein Engineering for Synthetic Biology Pimchai Chaiyen (Vidyasirimedhi Institute of Science and Technology (VISTEC), Thailand)/Weixin Tang (University of Chicago)/Jay Keasling (University of California, Berkeley) 7.    Directed Evolution for Enzyme Optimization Yang Yang (University of California Santa Barbara)/Leilei Zhu (Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, China)/Miguel Alcalde (Institute of Catalysis, CSIC, Spain)/Chang Liu (University of California, Irvine) 8.    Protein engineering for Immunotherapy and other diseases Anna Wu (Beckman Research Institute, City of Hope)/Xue Gao (University of Pennsylvania)/Bingfei Yu (University of Southern California)/Wilson Wong (Boston University) 9.    Repurposing Protein for Novel Chemistry and Applications Stefan Lutz (Codexis Inc)/Xiongyi Huang (Johns Hopkins University)/Xiaojing Gao (Stanford University)

46

3 Comments

🎤 uBriGene Presents Exclusive Sessions at SAPA 2024 @Philly CGT Annual Conference 🎤 🚀 We're thrilled to announce our participation at 2024 @Philly Cell and Gene Therapy Annual Conference with two exclusive sessions aimed at revolutionizing the field: 1️⃣ An Innovative Technology for High Yield and More Stable #CRISPR Guide RNA: Discover how our innovative approach of using in vitro transcription (IVT) in producing guide RNA (#gRNA) that can simplify the process while being more cost-effective and free of organic chemicals. Join us to delve into the future of precision gene editing. 2️⃣ How Could CDMO and Technology Innovations Make CGT Affordable: Dive into the intersection #CDMO of and technological advancements with uBriGene. Learn about our strategies to drive down costs without compromising quality or efficacy. Let's explore how cutting-edge technology can make #CellandGeneTherapy more accessible to all. 2024 @Philly Cell and Gene Therapy Annual Conference brings together the innovators and business leaders to foster collaborations and advance cell and gene therapy in the #GreaterPhiladelphia area. 💡 Join #uBriGene to be at the forefront of innovation and collaboration in the dynamic world of cell and gene therapy and let's make cutting-edge cell and gene technology more accessible!

3

So Exciting! Johnson & Johnson 's Harsha Gunawardena is teaming up with Protein Metrics, LLC to do a webinar on Novilytic's #Proteometer fueled by #MASC. See https://bit.ly/4eCpPQh to learn how Harsha and his Team utilize this great software and AI to accelerate Biopharmaceutical Characterization and Quantification using MASC !!!

42

3 Comments

Demonstrating the technical leadership of SK pharmteco! 🧬 Catch up with our team at ASGCT to discuss how SKPT can support your #cellandgene development!

9

1 Comment

Lake N. Paul, PhD. is in San Diego at the Biotechnology Innovation Organization #BIO2024 conference meeting with colleagues & future clients. Connect with him in person to learn about how, as a Collaborative Research Organization, we are best positioned to support your analytical program. #aav #genetherapy #rarediseases #biophysics #STEM #STEMPhilly #biochemistry #celltherapy #bioanalysisllc #PhillyBusiness #phillyscience

9

Come visit us in Boston next week! Empowered with relative affinity analysis as you conduct series of binding / blocking assays on the Beacon, it can be your workhorse for not just difficult antigen, but every-use antigen with much more accelerated pace. Any antigen, any species, most detailed functional screening of antibodies. Antibody discovery. Autoimmune autoantibody discovery. Vaccine development from patient samples. Who doesn’t need a good antibody? Try #Beacon optofluidic technology. Exquisite control, deepest insight.

19

🎉 Get Ready to Dive into Target Selection with Nikolai Suslov🌟 Join us in welcoming Nikolai Suslov, Senior Director of Protein Engineering at Phenomic, as our distinguished facilitator for the roundtable discussion on Target Selection at Antibody Therapeutics Xchange in Boston 2024! 🗓️ Date: June 17th, 2024 📍 Location: Woburn Hilton Hotel, 2 Forbes Road, Woburn, US 📌 Secure your Complimentary Pass and reserve your seat alongside industry leaders: https://bit.ly/3vjUhhb With over a decade of experience in biotherapeutic discovery and optimization, Nikolai brings unparalleled expertise to guide you through the strategies for target selection. Here's what you can expect: 🔍 Insights into what a protein engineer brings when selecting therapeutic targets. 💡 Discover new bioinformatic databases for target ranking. 🎯 Valuable tips on Tabs/Lens.org mining for generating tool mabs for target validation. * Agenda subject to change 💊 Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 #AntibodyTherapeutics #TargetSelection #BioTech #Pharma #Innovation #BostonEvent #ProteinEngineering #MolecularBiology #ScienceAndTechnology #ResearchAndDevelopment #MedicalAdvancements #HealthcareInnovation #Biopharmaceuticals #LifeSciences #DrugDevelopment #PrecisionMedicine #Biologics #DrugDiscovery #ScientificCommunity #IndustryLeadership #NetworkingEvent #BostonTech #HealthcareIndustry #MedicalResearch #InnovativeScience #ScientificAdvancements #hubXchange #Roundtable #FreePass #RegisterNow #ComplimentaryPass

4

Learn more about Nature's Toolbox, Inc. (NTx) innovations from Director of Technical Operations, Nathan Duval, PhD in this session with Genetic Engineering & Biotechnology News!

9

New Patent Alert! We’re proud to announce that GenNext Technologies has received its fourth and fifth United States Patent! One protects an exciting and proprietary means by which Fox® Protein Footprinting is combined with in-line molecular separation, such as liquid chromatography, to separate and individually label heterogeneous samples, comprising mixed conformers, multi-unit protein complexes, or other diverse protein populations. The other protects the company’s exclusive means and methods by which robust and reproducible in-cell radical protein footprinting studies are performed. These two new patents further establish GenNext as the pre-eminent company in high-resolution protein footprinting, enabling researchers to develop safer, more effective, and more affordable therapeutics. A heartfelt thank you to our dedicated GenNext Team for your relentless effort and innovation in advancing the field of structural biology research! #GenNext #Research #Science #ScientificResearch #Biotherapeutics #ProteinCharacterization #ResearchInnovation #HRPF #ProteinResearch #ScientificInnovation #Teamwork #ProteinStructure #StructuralBiology #Biochemistry #Proteomics #Biotechnology #Antibody #mAb

32

3 Comments

PTC was excited to learn, share and collaborate with other leading RNA experts at the recent 7th Annual RNA-Targeted Drug Discovery & Development Summit in Boston, MA, and the RNA at the Bench and Bedside IV conference in La Jolla, CA. Anu Bhattacharyya, Kerstin Effenberger, and Marla Weetall from our research team presented on ways PTC is leveraging its leading splicing platform to identify promising therapies for rare diseases with high unmet need. Learn more about our splicing platform here: https://bit.ly/4fi4w6L

135

1 Comment

One company optimizing protein conjugates, one company screening for optimal efficacy and therapeutic window of protein conjugates. Well played, #RESIBoston2024 #ADCs #startup #proteinconjugation

55

2 Comments

On January 8, 2025, Avidity Biosciences, Inc. announced its progress and planning for a transformational year in 2025. #DuchenneNews Major anticipated milestones include executing on three potentially registrational programs, filing a Biologics License Application for delpacibart zotadirsen (del-zota) for people living with Duchenne mutations amenable to exon 44 skipping (DMD44), preparing for multiple product launches in DMD44, myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD) and building a global, fully integrated company to support a growing AOC pipeline in neuromuscular diseases and precision cardiology. Full press release: https://bit.ly/40hG1RF

5

The #biosecure act is bad legislation and anti-competitive and will force US #biotech companies to abandon strong and honest #CDMO partners without making us more secure. Longstanding, productive drug-discovery collaborations will inevitably be compromised by an ill-conceived initiative — all for short-term political gain. Patients in need of innovative medicines are the ones that will lose out; I urge leaders in the #biotech industry to stand up and be counted in opposition to this proposed legislation.

7

Our VP of Biochemistry & Chemical Biology Jacob Stuckey, PhD is presenting at American Association for Cancer Research’s Conference on Optimizing Therapeutic Efficacy & Tolerability through Cancer Chemistry today, 12/10 from 2 - 4 pm EST at Plenary Session 4: Drug Design and Optimization - New and emerging targets! Come learn more about our PPARg covalent inverse agonist, FX-909, #FlareTx’s lead candidate for the treatment of bladder cancer. Read more about our science & approach: https://lnkd.in/gRHddDE #biotech #oncology #drugdiscovery

55

1 Comment

Scientists at Merck & Co. demonstrated the use of #ssNMR to analyze the freezing process of biomacromolecule solutions, crucial for biopharmaceutical development. The technique identifies the crystallization of certain compounds and measures the pH and unfrozen water content in freeze concentrates. The findings, applied to a commercial monoclonal antibody formulation, establish ssNMR as a valuable tool for investigating biopharmaceutical attributes and aiding process optimization and formulation development. Read the article: https://lnkd.in/eBME_y-r #NMR #crystallization #pharma #biopharmaceutical

96

3 Comments

Navigating Biotech Finding is definitely challenges. Here are some great insights to de-risk your clinical development program and attract investment

1

1 Comment